echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > New long-term positive data for JAK inhibitor Olumiant in RA

    New long-term positive data for JAK inhibitor Olumiant in RA

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Baricitinib is sold under brands such as Olumiant.


    Rheumatoid Arthritis FDA

    Eli Lilly and partner Incyte revealed that their JAK inhibitor Olumiant maintains consistent safety in long-term analysis of patients with rheumatoid arthritis (RA)


    These patients received a total of 14,744 patient-years of treatment.


    In 14,744 patient-year exposures, the incidence rate remained stable over time, and the incidence of serious infections was found to be 2.


    thrombusHeart blood vessels

    Peter C.


     

    Original source:

    Original source:

    https:// href="https://" target="_blank" rel="noopener">https:// https://


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.